Baker SD - Search Results

1

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.

van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD, Sparreboom A. van Erp NP, et al. Among authors: baker sd. Clin Cancer Res. 2007 Dec 15;13(24):7394-400. doi: 10.1158/1078-0432.CCR-07-0346. Clin Cancer Res. 2007. PMID: 18094422 Clinical Trial.

2

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Sparreboom A, et al. Among authors: baker sd. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):183-90. doi: 10.1016/s1570-0232(02)00167-8. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 12031845

3

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A. Baker SD, et al. J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8. doi: 10.1093/jnci/94.24.1883. J Natl Cancer Inst. 2002. PMID: 12488482

4

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD. Sparreboom A, et al. Among authors: baker sd. Clin Cancer Res. 2003 Jan;9(1):151-9. Clin Cancer Res. 2003. PMID: 12538463

5

Distribution of paclitaxel in plasma and cerebrospinal fluid.

Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: baker sd. Anticancer Drugs. 2003 Jun;14(5):365-8. doi: 10.1097/00001813-200306000-00007. Anticancer Drugs. 2003. PMID: 12782943 Clinical Trial.

6

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Mathijssen RH, et al. Among authors: baker sd. Clin Cancer Res. 2003 Aug 15;9(9):3246-53. Clin Cancer Res. 2003. PMID: 12960109

7

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Among authors: baker sd. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

8

Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.

Ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, Figg WD, Sparreboom A. Ten Tije AJ, et al. Among authors: baker sd. Clin Pharmacol Ther. 2003 Nov;74(5):509-10. doi: 10.1016/j.clpt.2003.08.004. Clin Pharmacol Ther. 2003. PMID: 14586392 Clinical Trial. No abstract available.

9

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.

Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A. Baker SD, et al. Anal Biochem. 2004 Jan 15;324(2):276-84. doi: 10.1016/j.ab.2003.09.038. Anal Biochem. 2004. PMID: 14690692

10

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Baker SD, et al. Clin Cancer Res. 2004 Mar 15;10(6):1976-83. doi: 10.1158/1078-0432.ccr-0842-03. Clin Cancer Res. 2004. PMID: 15041715 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

270 results

Search Page

Filters